A Novel Approach to Alzheimer’s Drug Therapy, Phase 2a Clinical Trial Results of T3D-959 to be Presented by T3D Therapeutics at CTAD

Share Article

Cognitive testing and neuroimaging results from a recently completed Phase 2a clinical trial of T3D-959 in mild to moderate Alzheimer’s patients will be presented at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Diego, CA from December 8-10. T3D-959, a novel small molecule drug candidate, is designed to activate two nuclear receptors regulating brain glucose energy and lipid metabolism.

T3D Therapeutics, Inc., a clinical stage drug development company engaged in the development of a new orally administered treatment for Alzheimer’s disease (AD), today announced that CEO, John Didsbury, will be presenting cognitive testing and neuroimaging results of a Phase 2a clinical trial of T3D-959 in mild to moderate Alzheimer’s patients at CTAD 2016. Preliminary results of a 26-week open label extension of the main study will also be presented. The oral presentation will take place on Friday, December 9th in San Diego, CA.

Presentation Details:

Title:     OC39 - Cognitive Improvement in Mild to Moderate Alzheimer’s Patients: Preliminary Results of an Open Label, Phase 2A Study of T3D-959
Date/Time:     December 9, 2016, 11:15am (PST)
Location:     Marriott Marquis San Diego Marina, Marina Ballroom G

Presenter, John Didsbury states, “AD is a disease involving multiple pathologies. In addition to dysfunctional glucose energy as a result of insulin and IGF-1 resistance and dysfunctional lipid metabolism (e.g. cholesterol and sphingolipids), AD pathology encompasses a plethora of neurodegenerative ‘triggers’ including; beta amyloid plaques, tau neurofibrillary bundles, oxidative stress, neuroinflammation and neurotransmitter deficits. A key tenet of the neuro-metabolic approach to treating AD with T3D-959 is that AD involves a massive positive feedback loop of altered glucose/lipid metabolism alterations and the above-mentioned pathological sequelae. The objective of T3D-959 treatment is to break this feedback loop by improving both energy and lipid metabolic dysfunctions.”

In previous pre-clinical studies T3D-959 treatment of i.c. STZ rats, a model of sporadic AD, restored neurocognitive function and reversed brain atrophy.

About T3D Therapeutics, Inc.

T3D Therapeutics, Inc. is a privately-held, Research Triangle Park, NC-based company incorporated in 2013. The Company has an exclusive license to T3D-959, its lead product candidate, and a platform of structurally-related molecules. T3D Therapeutics’ mission is to develop and commercialize T3D-959 for the treatment of Alzheimer’s disease and Mild Cognitive Impairment. The Company believes, that due to its novel mechanism of action, T3D-959 may also have therapeutic benefit in other central nervous system and other neurodegenerative diseases.

T3D-959, the Company’s lead product candidate, is a small molecule, orally-delivered, brain-penetrating PPAR delta / gamma dual nuclear receptor agonist. T3D-959 is designed to improve neuro-metabolic dysfunction present in Alzheimer’s disease. T3D-959 primarily activates PPAR delta and secondarily PPAR gamma. Unlike PPAR gamma, PPAR delta is universally expressed in the brain, particularly in areas of high energy metabolism. T3D-959 readily crosses the blood-brain barrier. In published preclinical studies T3D-959 has been observed to regulate Abeta, tau, oxidative stress and inflammation providing significant improvement in memory and motor function.

For more information, please visit http://www.t3dtherapeutics.com/.

Forward-Looking Statements

Statements contained in this release that are not statements of historical fact are forward-looking statements, including those statements relating to the Company's expectations regarding clinical studies and developments, and the future potential of its product candidates, including T3D-959, and other statements that are predictive in nature or that depend upon or refer to future events or conditions. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important risks and uncertainties, and assumptions, which if they do not materialize or prove incorrect, may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company’s results include, but are not limited to, uncertainties and/or unexpected results related to research and development and clinical testing, the timing, costs and uncertainty of obtaining any required regulatory approvals, changes in the regulatory landscape, uncertainties related to obtaining additional capital as needed to meet the Company’s needs on acceptable terms, or at all, the absence of any guarantee of product demand, market acceptance or competitive advantage for any of the Company’s product candidates, if approved, and certain trade, legal, social and economic risks. Any forward-looking statement in this release speaks only as of the date on which it is made, and the Company assumes no obligation to update or revise any such forward-looking statement.

Investor Contact

John Didsbury, Ph.D., CEO
T3D Therapeutics, Inc.
Email: info (at) t3dtherapeutics (dot) com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

John Didsbury